Advice

Advice

NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer because no evidence submission was received from Roche Products for the technology.

  • National Institute for Health and Care Excellence (NICE)